SILO Pharma Inc [NASDAQ: SILO] slipped around -0.07 points on Tuesday, while shares priced at $0.73 at the close of the session, down -9.27%.
Compared to the average trading volume of 459.04K shares, SILO reached a trading volume of 11405027 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about SILO Pharma Inc [SILO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SILO shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SILO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 1.28, with the Price to Cash per share for the same quarter was set at 0.66.
How has SILO stock performed recently?
SILO Pharma Inc [SILO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.03. With this latest performance, SILO shares gained by 2.32% in over the last four-week period, additionally sinking by -47.73% over the last 6 months – not to mention a drop of -18.37% in the past year of trading.
SILO Pharma Inc [SILO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and SILO Pharma Inc [SILO] shares currently have an operating margin of -7253.59% and a Gross Margin at -1226.47%. SILO Pharma Inc’s Net Margin is presently recorded at -6789.22%.
SILO Pharma Inc (SILO) Capital Structure & Debt Analysis
According to recent financial data for SILO Pharma Inc. ( SILO), the Return on Equity (ROE) stands at -90.03%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -66.64%, reflecting the company’s efficiency in generating profits from its assets. Additionally, SILO Pharma Inc’s Return on Invested Capital (ROIC) is -99.55%, showcasing its effectiveness in deploying capital for earnings.
SILO Pharma Inc (SILO) Efficiency & Liquidity Metrics
Based on SILO Pharma Inc’s (SILO) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
SILO Pharma Inc (SILO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, SILO Pharma Inc. (SILO) effectively leverages its workforce, generating an average of -$1633333.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 6.07% and a Quick Ratio of 6.07%, indicating strong ability to cover short-term liabilities.
Earnings analysis for SILO Pharma Inc [SILO]
With the latest financial reports released by the company, SILO Pharma Inc posted -0.36/share EPS, while the average EPS was predicted by analysts to be reported at -0.2/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.16. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SILO.
Insider trade positions for SILO Pharma Inc [SILO]
There are presently around $4.30%, or 4.40%% of SILO stock, in the hands of institutional investors. The top three institutional holders of SILO stocks are: VIRTU FINANCIAL LLC with ownership of 41848.0 shares, which is approximately 1.3709%. FINANCIAL ADVOCATES INVESTMENT MANAGEMENT, holding 23938.0 shares of the stock with an approximate value of $$23938.0 in SILO stocks shares; and FINANCIAL ADVOCATES INVESTMENT MANAGEMENT, currently with $$16334.0 in SILO stock with ownership which is approximately 0.5351%.
